CRECON MEDICAL ASSESSMENT

JP

Presentations

Presentation

  • Ikeda S, Kobayashi M. Evaluation on long term prognosis model of patients with type II diabetes mellitus by estimate. The 52th Annual meeting of the Japanese diabetes society, Osaka, Japan. 21th Mar, 2009. (in Japanese)

  • Konno S, Togawa D, Kamae I, Inoue S, Kikuchi S. Burden of illness of conservative medical management of osteoporotic vertebral compression fractures in Japan. ISPOR 14th Annual International Meeting, Orlando, FL, USA. 18 May, 2009.

  • Inoue S, Okuda S, Yamaguchi T. Economic impact of edaravone therapy for patients with lacunar infarction in Japan. ISPOR 14th Annual International Meeting. Orland, USA.2009.

  • Hirakawa K, Kobayashi M, Inoue S. Economic analysis of minimally invasive surgery-total hip arthroplasty in Japan. 15th Health research forum. Tokyo, Japan.15th Nov, 2008. (in Japanese)

  • Inoue S, Kobayashi M, Sugaya K. Economic impact of overactive bladder symptoms in Japan. ISPOR 3rd Asia-Pacific Conference, Seoul, South Korea, 2008.

  • Konno S, Togawa D, Kamae I, Inoue S, Kikuchi S. Burden of illness of conservative medical management of osteoporotic vertebral compression fractures in Japan. ISPOR 14th Annual International Meeting. Orland, USA.2008.

  • Ikeda S, Ikeda K, Yamagishi T, Maeyama K, Miura D, Yokoyama T, Morikawa Y, Jo H, Kobayashi M. Examination of the respiratory syncytial virus infection hospitalization medical cost by the presence or absence of Palivizumab administration. 14th Japan society of pharmacoepidemiology. Tokyo, Japan. 8th Nov, 2008. (in Japanese)

  • Ikeda S, Kobayashi M, Tajima N. Cost effectiveness analysis of voglibose in the type II diabetes mellitus prophylaxis for impaired glucose tolerance (IGT). 14th Japan society of pharmacoepidemiology. Tokyo, Japan.8th Nov, 2008. (in Japanese)

  • Inoue S, Kobayashi M, Sugaya K. Economic impact of Overactive Bladder symptoms in Japan. ISPOR 3rdAsia-pacific conference, Seoul, Korea. 7-9 September, 2008.

  • Ikeda S, Kobayashi M, Tajima N. Cost-effectiveness analysis of voglibose in prevention of type2 diabetesin Japanese with impaired glucose tolerance (IGT). ISPOR 3rdAsia-pacific conference, Seoul, Korea.7-9 September 2008.

TOPPresentation
TOP
費用対効果分析

Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals
疾病負担分析

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time
リアルワールドデータ

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis
教育及び各種コンサルティング

Education
and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA